Gaucher Disease

Worldwide license agreement extends Zavesca partnership

Published in Drug Week, January 10th, 2003

Actelion, Ltd., and Oxford GlycoSciences, plc, announced that a license agreement has been signed extending the parties' existing European marketing relationship and granting Actelion worldwide marketing rights to Zavesca (miglustat), with the exception of Israel.

Zavesca is a small molecule developed by OGS for the treatment of patients with mild-to-moderate type 1 Gaucher disease for whom enzyme replacement therapy (ERT) is unsuitable.

Under the terms of this agreement, which is for an initial 5 years, Actelion will be the marketing license holder and will be responsible for all regulatory and marketing activities and for booking sales of Zavesca. ...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2003-01-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry